Search

The article presents the study which examines T-cell dysfunction in patients with HIV infection and are undergoing impaired recovery of CD4 cells. It states that CD4 T-cell recovery is slow in some HIV-infected patients despite suppression of viral replication. It hypothesizes that T-cell dysfunction would increase in HIV-1 infected patients.

The article evaluates three cycles of interleukin-2 (IL) on clinical and immunologic outcomes, utilizing a CD4 T-cell count of <350 cells/mm³ after treatment interruption (TI) following antiretroviral therapy. IL-2 recipients have higher CD4 counts during TI for 48 weeks with a waning of the CD4 effect by 72 weeks. After TI, a higher viral set point and drug resistance mutations at virologic rebound were related with a shorter time to CD4 T-cell count of less than 350 cells/mm³.

Examines the potential contribution of the thymus to CD4[sup+] T-lymphocyte in HIV-infected patients receiving intermittent interleukin-2 therapy. Method used in the estimation of thymic size; Mechanism underlying the CD4[sup+] T-lymphocyte expansion; Major pathogens for AIDS patients.

The article investigates the long-term impact of interleukin (IL)-2 therapy on HIV infection by researchers from Milan, Italy. In this study, the researchers focused on immunologic and virologic consequences and long-term impact of intermittent IL-2 therapy on HIV-infected patients. In conclusion, the correlates of IL-2-induced immunoogic reconstitution, in addition to the restoration of a normal number of circulating CD4 T-cells, remain to be fully uncovered.